Clearmind Medicine stock surges after Polyrizon intranasal delivery deal

Clearmind Medicine Inc. (NASDAQ:CMND) and Polyrizon Ltd. (NASDAQ:PLRZ) announced a strategic development agreement on Friday, leading to a 10.2% surge in Clearmind's stock and a 3% rise in Polyrizon's shares during premarket trading. The collaboration aims to enhance the delivery of Clearmind's lead drug candidate, MEAI (5-methoxy-2-aminoindane), using Polyrizon's intranasal hydrogel technology. MEAI is a non-hallucinogenic neuroplastogen designed to treat addiction-related disorders, weight loss, and other central nervous system conditions. The partnership seeks to leverage the advantages of intranasal delivery, including enhanced nasal residence time, targeted delivery, and improved patient usability. This route may bypass first-pass metabolism, potentially allowing for faster absorption and lower effective doses compared to oral administration. Dr. Adi Zuloff-Shani, CEO of Clearmind, expressed enthusiasm about the partnership, highlighting the potential for improved bioavailability and therapeutic efficacy. Tomer Izraeli, CEO of Polyrizon, emphasized the targeted and efficient delivery capabilities of their intranasal technology. The companies also noted that Polyrizon is a related party to Clearmind under Canadian securities regulations, with Clearmind relying on exemptions for the transaction.